Krazati access in Jordan: the JFDA named-patient pathway
How patients in the Hashemite Kingdom of Jordan legally obtain Krazati (adagrasib) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Jordan access Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy, and KRAS G12C-mutated locally advanced or metastatic colorectal cancer in combination with cetuximab through the JFDA named-patient pathway, a Jordan Food and Drug Administration-administered mechanism that allows a Jordanian-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in JOD.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Jordanian patients need Krazati through the named-patient pathway
The Hashemite Kingdom of Jordan operates a structured pharmaceutical regulatory environment. Krazati (adagrasib) is regulated through JFDA (Jordan Food and Drug Administration) channels, and a Jordanian family asking for Krazati is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Krazati's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. MedNet Jordan and Globemed Jordan-administered private plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Jordan or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the JFDA named-patient pathway is the mechanism that connects a Jordanian-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Krazati is an oral covalent KRAS G12C inhibitor administered twice daily that locks the mutated KRAS protein in the inactive GDP-bound state, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
Current regulatory status of Krazati in Jordan
Krazati (adagrasib; Bristol Myers Squibb following the Mirati Therapeutics acquisition) is an oral covalent KRAS G12C inhibitor for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer after at least one prior systemic therapy, and KRAS G12C-mutated locally advanced or metastatic colorectal cancer in combination with cetuximab. As of 2026-05-31, no public JFDA record of a Jordan marketing authorisation for adagrasib has been identified.
Bristol Myers Squibb maintains a regional commercial structure in Jordan; whether adagrasib has been notified for regional registration depends on BMS's pipeline prioritisation. Until a Jordan registration is gazetted, access proceeds under Article 34 of the Drug and Pharmacy Law No. 12 of 2013 through a JFDA Drug Directorate import-permit file. Source: JFDA.
The KRAS G12C testing prerequisite is determinative for file eligibility. The file specifies the molecular pathology report identifying KRAS G12C, the tumour primary (NSCLC or colorectal), and the line of therapy. For the colorectal indication the file specifies the combination-with-cetuximab dosing plan. Adagrasib has documented CYP3A4-mediated drug-drug-interaction caveats and a long-QT-syndrome ECG-monitoring requirement; the file references the monitoring plan.
Last verified by ARCH-74: 2026-05-31. Quarterly JFDA bulletin scan picks up class-level (KRAS-G12C-inhibitor) safety updates if gazetted.
Named tertiary centres in Jordan where Krazati is dispensed
Adagrasib is an adult medical oncology product; in Jordan the dispensing centres are:
- King Hussein Cancer Center (KHCC), Al-Jubaiha, Amman - Department of Medical Oncology with subspecialty thoracic-oncology and colorectal-oncology clinics; the JCI-accredited national cancer referral centre. KHCC maintains molecular-pathology testing for KRAS, EGFR, ALK, and related drivers on site. Source: King Hussein Cancer Center.
- Jordan University Hospital, Amman - Department of Medical Oncology with thoracic and colorectal sub-clinics.
- King Abdullah University Hospital, Irbid - Department of Medical Oncology; northern Jordan academic tertiary.
- Royal Medical Services - King Hussein Medical Center, Amman - Department of Medical Oncology.
- Istishari Hospital, Amman - private tertiary multi-specialty with medical oncology.
For the NSCLC indication, thoracic-oncology MDT review at KHCC or JUH typically anchors the file; for the colorectal indication, the GI-oncology MDT with cetuximab co-prescription anchors the file. Molecular-pathology turnaround for KRAS G12C testing at KHCC is in-house with same-week turnaround.
Local pricing reference for Krazati in Jordan
US WAC reference for Krazati (adagrasib, 200 mg oral tablets) is in the order of USD 18,000 to USD 22,000 per 30-day supply at the FDA-labelled 600 mg twice-daily regimen. Source: Krazati FDA Prescribing Information.
No public JOD reference price for adagrasib has been observed on JFDA, the MOH controlled-medicine list, or major-importer published lists as of 2026-05-31. We issue a JOD-converted itemised quotation at intake at the published Jordan Central Bank USD/JOD rate; JOD is pegged to USD at approximately 0.71 JOD per USD.
Price snapshot date: 2026-05-31. For the colorectal indication, the cetuximab co-prescription is locally sourced (Erbitux is regionally registered) and is not part of the adagrasib import file; the combination cost line in the patient quotation reflects local cetuximab pricing plus the cross-border adagrasib line.
Country-specific access barriers for Krazati in Jordan
The KRAS G12C testing prerequisite is the practical first step in any Krazati case in Jordan; the patient must have molecular-pathology confirmation of the driver mutation before the JFDA file proceeds. KHCC, JUH, and KAUH run KRAS G12C testing in-house; smaller centres typically refer specimens to KHCC or to a commercial reference laboratory. Turnaround is normally one week; the file references the laboratory report.
Public-sector funding posture: KHCC's funding model (King Hussein Cancer Foundation grants, MOH referral for nationals lacking means, RMS coverage for military, private insurance for insured, self-pay) is the principal mechanism for KHCC-managed oncology patients. For non-KHCC patients, MOH and RMS formulary inclusion of novel targeted oncologics is conducted on a case-by-case basis; adagrasib is not on the standard formulary as of 2026-05-31. Source: KHCF.
Private-insurance coverage of novel KRAS-inhibitor therapy in Jordan is policy-specific. Insurers including MetLife Jordan, Arab Orient Insurance, and Jordan Insurance Company typically require pre-authorisation and impose annual caps that constrain multi-month-targeted-therapy continuation. Refugee-population context (Syrian, Palestinian, Iraqi) is material; UNHCR-supported procurement covers some oncology referrals to KHCC but does not customarily extend to novel oral targeted therapies.
The QT-prolongation pharmacovigilance signal in the FDA label requires baseline and periodic ECG monitoring; the file specifies the ECG schedule. CYP3A4 interactions are managed by reviewing concomitant medications before dispensing; the dispensing pharmacy at KHCC operates an automated interaction check on every fill. Each JFDA permit covers a single supply period (commonly three months); continuous-therapy patients re-apply per cycle.
Recent local regulatory news touching Krazati or its drug class in Jordan
No JFDA bulletin specifically naming adagrasib or the KRAS-G12C-inhibitor class has been observed in the last twelve months on the JFDA Recalls and Safety Communications page as of 2026-05-31. Adjacent context relevant to the workflow:
- FDA accelerated-approval-to-full-approval conversion processes for adagrasib's colorectal-cancer-in-combination-with-cetuximab indication remain in dialogue at the US level; regional approvals downstream may follow the FDA final action. Source: FDA Drugs@FDA database.
- JFDA Drug Directorate continues to update the digital-permit-submission workflow; KHCC's pharmacy is the principal Jordan-side institutional contact for molecular-oncology imports. Source: JFDA.
What your physician needs to provide
For a Jordanian-licensed specialist prescribing Krazati through the JFDA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy, and KRAS G12C-mutated locally advanced or metastatic colorectal cancer in combination with cetuximab, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Krazati is the appropriate next step given an oral covalent KRAS G12C inhibitor administered twice daily that locks the mutated KRAS protein in the inactive GDP-bound state.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Krazati (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Jordanian license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
Common questions about Krazati in Jordan
Will MedNet Jordan and Globemed Jordan-administered private plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Krazati is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by JFDA? The JFDA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; JFDA review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Jordanian-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. Jordan Medical Council and the JFDA verifies the active license; the JFDA application records both the prescribing physician and the dispensing facility.
Can I receive Krazati at home? The dispensing facility must be Jordanian-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Krazati cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace JFDA, and we do not replace your dispensing pharmacy. For Krazati specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Jordan, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Krazati case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the JFDA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Krazati is an oral KRAS G12C inhibitor; named-patient files document the KRAS G12C mutation status from a validated assay, prior systemic therapy, and the baseline cardiac function (QTc prolongation is on the FDA warnings list). Jordan thoracic and GI oncology programmes increasingly run upfront molecular profiling that supports this build.
Next step
If your Jordanian physician has prescribed Krazati and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.